trending Market Intelligence /marketintelligence/en/news-insights/trending/vXzdZHtKPK6nVUg0sM8T7Q2 content esgSubNav
In This List

Endo seeks US FDA approval for injection to treat skin condition

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Endo seeks US FDA approval for injection to treat skin condition

Endo International PLC filed an application with the U.S. Food and Drug Administration for the approval of Xiaflex injection to treat cellulite in the buttocks, a skin condition for which there is no approved drug-based treatment.

The share price of Dublin-based pharmaceutical company was up 30.1% as of 12:17 p.m. ET on Sept. 6.

The company's biologics license application is backed by results of two phase 3 trials, Release-1 and Release-2, that showed the injection improved the appearance of cellulite in the buttocks compared to placebo. Cellulite is caused by fat deposits pushing through the connective tissue beneath the skin, making the skin look dimpled and lumpy.

Xiaflex, or collagenase clostridium histolyticum, was originally approved by the FDA in 2010 for the treatment Dupuytren's contracture, which causes the connective tissue in the hand to thicken and tighten.

The U.S. regulator has 60 days to review the filing and decide if the application is complete and acceptable.